Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US

被引：0
|
作者：
Aly, Abdalla
Bapat, Bela
Ray, Saurabh
Chen, Zhiyong
Botteman, Marc
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3386
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Agrawal, Vaibhav
    Croslin, Cindy
    Beltran, Asuscena L.
    Zhang, Jianying
    Palmer, Joycelynne
    Quy Huynh-Tran
    Hernandez, Rochelle
    Thomas, Sandra
    Robbins, Marjorie
    Aribi, Ahmed
    Ali, Haris
    Stein, Anthony S.
    Budde, Elizabeth L.
    Al Malki, Monzr M.
    Marcucci, Guido
    BLOOD, 2022, 140 : 6235 - 6236
  • [42] Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
    Daver, Naval G.
    Assi, Rita
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Ravandi, Farhad
    Konopleva, Marina Y.
    Kadia, Tapan M.
    Borthakur, Gautam
    Jabbour, Elias J.
    DiNardo, Courtney D.
    Velasquez, Michelle
    Kelly, Mary
    Ning, Jing
    Gonzalez, Graciela M. Nogueras
    Pierce, Sherry A.
    Gombos, Dan
    Estrov, Zeev E.
    Kornblau, Steven M.
    Zhang, Weiguo
    Andreeff, Michael
    BLOOD, 2018, 132
  • [43] Economic burden of relapsed/refractory chronic lymphocytic leukemia
    Guerin, Annie
    Ray, Saurabh
    Gauthier, Genevieve
    Hsu, Ling-I
    Zhdanava, Maryia
    Heroux, Julie
    Wu, Eric
    LEUKEMIA & LYMPHOMA, 2015, 56 : 40 - 41
  • [44] OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Dilley, Kimberley
    Laille, Eric
    Gong, Jing
    de Menezes, Daniel Lopes
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [45] Predictive Biomarkers of Response to the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Decitabine in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
    Zeidan, Amer M.
    Ridinger, Maya
    Croucher, Peter J. P.
    Samuelsz, Errin
    Erlander, Mark
    Ruffner, Katherine L.
    Wang, Eunice S.
    BLOOD, 2021, 138
  • [46] OUTCOMES OF SALVAGE CHEMOTHERAPY REGIMENS IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
    Tak, Himangi
    Trivedi, Maharshi
    Joshi, Nitin
    Panchal, Harsha
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S553 - S553
  • [47] Time-sequential chemotherapy as treatment for refractory or relapsed adult acute myeloid leukemia (AML).
    Martino, R
    Altés, A
    Guárdia, R
    Sureda, A
    Brunet, S
    Briones, J
    Sierra, J
    BLOOD, 1998, 92 (10) : 217B - 217B
  • [48] Inotuzumab Ozogamicin (Besponsa®) for Patients with relapsed or refractory acute lymphoblastic Leukemia (r/r ALL)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 66 - 66
  • [49] Patterns of failure for refractory or relapsed acute myeloid leukemia (AML) displaying a normal karyotype.
    Thomas, X
    Chelghoum, Y
    Le, QH
    Revesz, D
    Elhamri, M
    Troncy, J
    Michallet, M
    BLOOD, 2003, 102 (11) : 248B - 248B
  • [50] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali
    Rodriguez, Vilmarie
    O'Brien, Maureen Megan
    McNeer, Jennifer Lynn
    Loh, Mignon L.
    Rheingold, Susan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345